Publication

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Authors not recorded

Ann Oncol2015PMID 25899785PMC5006511stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

cancerLung Adenocarcinomacivic_curation1.00
cancerLung Non-Small Cell Carcinomacivic_curation1.00
drugDacomitinibcivic_curation1.00
geneERBB2civic_curation1.00
variantERBB2 Amplificationcivic_curation1.00
variantERBB2 G778_P780dupcivic_curation1.00
variantERBB2 M774DELINSWLVcivic_curation1.00
variantERBB2 Y772_A775DUPcivic_curation1.00

Curated evidence

Evidence citing this paper (6)

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 G778_P780dup2
Dacomitinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1048 In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID1892 Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781i… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
ERBB2 Y772_A775DUP2
Dacomitinib	Lung Adenocarcinoma	Predictive	C	Does Not Support Sensitivity Response	3	rejected	EID1049 In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, a cohort of 12 cases with the AYVM insertion did not show any partial responses to dacomitinib, in contras… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1893 Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insY… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
ERBB2 Amplification1
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1891 Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic
ERBB2 M774DELINSWLV1
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID1894 Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A… (full text at CIViC) PMID 25899785 · Kris et al., 2015 · Open in CIViC	civic